Abstract

Pharmacogenomics has emerged as a cornerstone of precision medicine, enabling safer and more effective 
prescribing through the identification of genetic determinants of drug response. Proteogenomics extends this 
approach by incorporating protein expression, modification, and functional data, offering a more comprehensive 
understanding of interindividual variability in therapeutic outcomes. This review examines the integration of 
pharmacogenomics through proteogenomics in primary care, focusing on clinical workflows, patient-centered 
outcomes, and cost-effectiveness. Evidence indicates that both pre-emptive and reactive testing models can support 
medication optimization, reduce adverse drug reactions, and improve adherence and clinical outcomes across 
multiple therapeutic areas, particularly psychiatric, respiratory, and cardiovascular conditions. Integration with 
electronic health records and clinical decision-support systems enhances real-time prescribing guidance and 
longitudinal patient management. Economic analyses suggest that pharmacogenomic-guided medication 
management can be cost-effective and may reduce healthcare utilization, although the high cost of proteomic 
assays and limited reimbursement remain barriers. Implementation challenges include a lack of workflow 
standardization, insufficient clinician training, limited population diversity in reference datasets, and translational 
gaps between research and routine practice. Strengthening implementation science, expanding diverse cohort 
studies, and developing standardized reporting frameworks will be essential to realizing the full clinical and 
economic potential of proteogenomics-enabled pharmacogenomics in primary care.